Clinical and genomic features of ALK fusion‐positive and ALK fusion‐negative NSCLC and non‐NSCLC cases
| Parameter . | NSCLC . | Non‐NSCLC . | Total . |
|---|---|---|---|
| Total cases sequenced, n (%) | 21,522 (18.8%) | 92,678 (81.2%) | 114,200 |
| Gender, female/male | 52.6%/47.4% | 59.2%/40.8% | |
| Age | |||
| Mean | 55.4 | 43.0 | |
| Median | 56 | 47 | |
| Range | 15–95 | 0–87 | |
| Number of cases with ALK rearrangements | 675 (3.1%) | 201 (0.2%) | 876 (0.8%) |
| Total number of ALK rearrangements | 680 | 204 | 884 |
| Fusions | 615 (90.4%) | 173 (84.8%) | 788 (89.1%) |
| Other rearrangements | 65 (9.6%) | 31 (15.2%) | 96 (10.9%) |
| EML4 fusion partner frequency | 568 (83.5%) | 63 (30.9%) | 631 (71.4%) |
| Parameter . | NSCLC . | Non‐NSCLC . | Total . |
|---|---|---|---|
| Total cases sequenced, n (%) | 21,522 (18.8%) | 92,678 (81.2%) | 114,200 |
| Gender, female/male | 52.6%/47.4% | 59.2%/40.8% | |
| Age | |||
| Mean | 55.4 | 43.0 | |
| Median | 56 | 47 | |
| Range | 15–95 | 0–87 | |
| Number of cases with ALK rearrangements | 675 (3.1%) | 201 (0.2%) | 876 (0.8%) |
| Total number of ALK rearrangements | 680 | 204 | 884 |
| Fusions | 615 (90.4%) | 173 (84.8%) | 788 (89.1%) |
| Other rearrangements | 65 (9.6%) | 31 (15.2%) | 96 (10.9%) |
| EML4 fusion partner frequency | 568 (83.5%) | 63 (30.9%) | 631 (71.4%) |
Abbreviation: NSCLC, non‐small cell lung cancer.
Clinical and genomic features of ALK fusion‐positive and ALK fusion‐negative NSCLC and non‐NSCLC cases
| Parameter . | NSCLC . | Non‐NSCLC . | Total . |
|---|---|---|---|
| Total cases sequenced, n (%) | 21,522 (18.8%) | 92,678 (81.2%) | 114,200 |
| Gender, female/male | 52.6%/47.4% | 59.2%/40.8% | |
| Age | |||
| Mean | 55.4 | 43.0 | |
| Median | 56 | 47 | |
| Range | 15–95 | 0–87 | |
| Number of cases with ALK rearrangements | 675 (3.1%) | 201 (0.2%) | 876 (0.8%) |
| Total number of ALK rearrangements | 680 | 204 | 884 |
| Fusions | 615 (90.4%) | 173 (84.8%) | 788 (89.1%) |
| Other rearrangements | 65 (9.6%) | 31 (15.2%) | 96 (10.9%) |
| EML4 fusion partner frequency | 568 (83.5%) | 63 (30.9%) | 631 (71.4%) |
| Parameter . | NSCLC . | Non‐NSCLC . | Total . |
|---|---|---|---|
| Total cases sequenced, n (%) | 21,522 (18.8%) | 92,678 (81.2%) | 114,200 |
| Gender, female/male | 52.6%/47.4% | 59.2%/40.8% | |
| Age | |||
| Mean | 55.4 | 43.0 | |
| Median | 56 | 47 | |
| Range | 15–95 | 0–87 | |
| Number of cases with ALK rearrangements | 675 (3.1%) | 201 (0.2%) | 876 (0.8%) |
| Total number of ALK rearrangements | 680 | 204 | 884 |
| Fusions | 615 (90.4%) | 173 (84.8%) | 788 (89.1%) |
| Other rearrangements | 65 (9.6%) | 31 (15.2%) | 96 (10.9%) |
| EML4 fusion partner frequency | 568 (83.5%) | 63 (30.9%) | 631 (71.4%) |
Abbreviation: NSCLC, non‐small cell lung cancer.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
